Veracyte, Inc. (NASDAQ:VCYT) Q1 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to Veracyte, Inc. first quarter 2026 financial results webcast call. At this time, all participants are in a listen-only mode.
Veracyte Inc. (VCYT)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 3,053,818 | $98,363,488 | -22% | 0.76% |
| 2. | Alyeska Investment Group Anand Parekh | 808,570 | $26,044,040 | +35% | 0.07% |
| 3. | Fisher Asset Management Ken Fisher | 736,270 | $23,715,255 | -8% | 0.01% |
| 4. | Deerfield Management James E. Flynn | 726,000 | $23,384,460 | 0.28% | |
| 5. | BAMCO Inc. Ron Baron | 655,522 | $21,114,364 | +2% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.33 | 60,000 | $980,094.00 | 159,761 | 2022-06-10 | Filing | |
| $35.19 | 2,000 | $70,389.20 | 2,000 | 2021-06-03 | Filing | |
| $5.32 | 2,500 | $13,288.00 | 10,000 | 2016-06-03 | Filing | |
| $5.48 | 2,500 | $13,693.25 | 7,500 | 2016-06-02 | Filing | |
| $5.46 | 2,500 | $13,641.75 | 5,000 | 2016-06-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $50.12 | 1,776 | $89,007.44 | 137,240 | 2026-06-04 | Filing | |
| $49.31 | 1,400 | $69,028.54 | 139,016 | 2026-06-04 | Filing | |
| $50.09 | 1,961 | $98,229.04 | 173,280 | 2026-06-04 | Filing | |
| $49.28 | 1,600 | $78,853.76 | 175,241 | 2026-06-04 | Filing | |
| $50.12 | 138,051 | $6,919,585.49 | 440,494 | 2026-06-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,172,618 | $424,290,027 | 0.01% | |
| 2. | 7,763,849 | $250,073,568 | 0.01% | |
| 3. | 5,496,370 | $177,038,065 | 0.28% | |
| 4. | 5,043,590 | $162,454,034 | 0.01% | |
| 5. | 4,444,730 | $143,164,753 | 0% |
News See All
Veracyte, Inc. (NASDAQ:VCYT) Q4 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Veracyte Fourth Quarter 2025 Financial Results Webcast.
Does Veracyte (VCYT) Offer Both Strength and Opportunity?
Brown Capital Management, an investment management company, released its fourth quarter 2025 investor letter for “The Brown Capital Management Small Company Fund”. A copy of the letter can be downloaded...
UBS Reaffirmed Buy Rating on Veracyte (VCYT) After Strong Q4 Testing Revenue
Veracyte, Inc. (NASDAQ:VCYT) ranks among the best innovative stocks to buy according to Wall Street analysts. On January 12, UBS reaffirmed its Buy rating for Veracyte, Inc.
13 Best Innovative Stocks to Buy According to Wall Street Analysts
Innovation is entering a new phase of rapid acceleration, according to ARK Invest.
Veracyte, Inc. (VCYT) Sees Analyst Support as Guggenheim Reaffirms Buy Rating
TheFly reported on January 5 that Guggenheim analyst Subbu Nambi raised the price target for VCYT to $50 from $45, maintaining a Buy rating on the stock.
15 High Growth Mid-Cap Stocks to Buy
The US stock market is shifting as President Trump reinforces his “America First” agenda through subsidies and incentives aimed at boosting domestic manufacturing.
Morgan Stanley Initiates Coverage Of Veracyte, Inc. (VCYT)
The Fly reported on December 2, 2025, that Morgan Stanley began covering Veracyte, Inc. (NASDAQ:VCYT) with an Underweight rating and a price target of $48, up from $40.
12 Best Genomics Stocks to Invest In
Companies that study DNA to improve people's lives are known as genomics stocks.
Veracyte, Inc. (NASDAQ:VCYT) Q3 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Veracyte Third Quarter 2025 Financial Results Conference Call.
Hedge Fund Resource Center